01801nas a2200241   4500000000100000000000100001008004100002260001500043653001700058653001700075653001500092100001200107700001100119700001100130700001300141700001600154245013100170856005500301300001000356490000700366520117200373022001401545       2026                            d  c2026-06-1310aCell biology10aNeuroscience10aStem cells1 aSong Qu1 aYue Wu1 aPu Sun1 aCui Song1 aYanyan Wang00aA patient-specific induced pluripotent stem cell and neural stem cell resource for angelman syndrome with 15q11.2-q13 deletion  uhttps://www.nature.com/articles/s41598-026-57826-2  a270020 v163 aAngelman syndrome (AS) is a severe neurodevelopmental disorder most commonly caused by a maternal deletion of the 15q11.2-q13 region, resulting in loss of ubiquitin protein ligase E3A (UBE3A) function. The development of targeted therapies and a deeper understanding of AS pathogenesis require the availability of genetically accurate human models. Here, we generated and characterized a novel induced pluripotent stem cell (iPSC) line from peripheral blood mononuclear cells of a female pediatric patient with genetically confirmed deletion-type AS. The iPSC line displayed a normal karyotype, expressed key pluripotency markers, and demonstrated trilineage differentiation potential. Efficient generation of neural stem cells establishes a foundational cellular resource for future investigations of neuronal maturation and disease-specific phenotypes. This well-validated iPSC and NSC resource provides a valuable and clinically relevant platform for elucidating the molecular pathophysiology of AS in a genetically accurate human cellular context and for high-throughput screening of therapeutic compounds targeting the predominant population of patients with AS.  a2045-2322